

Frusecare 40mg Tablets

Introduction



Company name: [Animalcare Limited](#)
Address: **Common Road**
Dunnington
York YO19 5RU
Telephone: **01904 487687**
Fax: **01904 487611**
Email: animalcare@animalcare.co.uk

Presentation

White, circular, biconvex, flat-faced tablets with bevelled edges, breakline and embossed F40 on one face, CP or DP on the reverse. Each tablet contains Frusemide 40 mg (Furosemide).

Uses

Frusecare tablets are for use in cats and dogs only, for the treatment of oedema associated with cardiac insufficiency, renal dysfunction and trauma. In animals with pulmonary oedema of cardiac origin, combined therapy with other medicinal products may be indicated. Furosemide is a potent diuretic with an onset of activity normally within 1 hour of administration and a duration of activity of approximately 4 hours.

Dosage and administration

For oral administration only. Dogs and cats above 4 kg bodyweight:

Dosage up to 5mg/kg bodyweight, or one Frusecare tablet per 8 kg bodyweight, 1 to 2 times daily with an interval of 6 to 8 hours between administrations.

For animals weighing between 4 and 8 kg, one half of one tablet should be administered. The tablets may be divided by breaking along the score line. For maintenance, the dosage should be reduced to 1-2mg/kg per day.

Contra-indications, warnings, etc

Do not use in animals weighing less than 4 kg.

Do not use in animals with acute glomerular nephritis, renal failure with anuria, electrolyte deficiency disease or in animals that have received an overdose of digitalis. Do not use concurrently with aminoglycoside antibiotics or corticosteroids.

Therapeutic efficacy may be impaired by increased intake of drinking water. Where the animal's condition permits, water intake should be restricted during treatment with Frusecare tablets.

Monitoring of plasma potassium levels is advisable during periods of prolonged treatment of combined therapy with cardiac glycosides. Potassium supplements may be necessary.

Frusecare tablets may be used in pregnant and lactating animals.

Concurrent administration with aminoglycoside antibiotics may result in ototoxicity. Concurrent administration with cephalosporin antibiotics may result in nephrotoxicity. Concurrent administration with sulphonamide antibacterials may result in sulphonamide allergy. Concurrent use of corticosteroids may increase the risk of hypokalaemia.

If you notice any serious effects or other effects not mentioned in this datasheet, please inform your veterinary surgeon.

Operator warnings: Wear gloves or wash hands immediately after handling the tablets.

General precautions: For animal treatment only. Keep out of the reach and sight of children.

Pharmaceutical precautions

Do not store above 25°C. Protect from light.

Disposal: Dispose of unused product and empty containers in accordance with guidance from your local waste regulation authority.

Legal category

POM-V

Packaging Quantities

Plastic containers of 1,000 tablets.

Further information

Do not use after the expiry date stated on the label.

To be supplied only on veterinary prescription.
UK authorised veterinary medicinal product.

Marketing Authorisation Holder (if different from distributor)

DECHRA Ltd, UK

Marketing authorisation number

Vm 10434/4066.

GTIN (Global Trade Item No)

1000 Tablets:
05055037400120